rais praluent estim inflect event drug
remain overweight rate share rais praluent estim follow
present odyssey outcom data weekend american
colleg cardiolog scientif session meet praluent cardiovascular outcom
data check box show risk reduct mace event
importantli show mortal benefit differenti factor repatha along
new price strategi think success improv access lead us
increas near- long-term estim deriv new price target
primari endpoint met surviv benefit import commerci recal
odyssey outcom evalu higher-risk popul amgn
fourier evalu effect praluent occurr mace patient
max-toler statin experienc ac within mo enrol given
high-risk popul sens broadli expect praluent would hit primari
endpoint reduc overal risk mace howev
sens investor anticip mortal benefit think
fact praluent associ lower risk all-caus mortal nomin
big deal particularli light repatha non-stat-sig surviv decrement
bigger benefit highest risk patient new strategi increas access
among higher-risk patient baselin mg/dl praluent therapi
reduc mace risk meaning associ reduc
risk all-caus mortal also announc new strategi intend improv
access offer addit rebat payer reduc barrier higher-risk
patient bring net price per year line new icer
valu assess acquiesc payer relianc icer may set
dubiou preced case see smart move reinvigor growth
see inflect event drug rais estim given
unexpect surviv benefit new price strategi think valu proposit
praluent increas meaning given payer negoti may take time
outcom data wont ad label next year treatment guidelin like
wont updat fall earliest would expect bulk volum
growth immedi appar still think near- long-term
revenu estim need come model end-us revenu
ahead consensu see rais pt
discount back
debt total capit
praluent may start matter think weekend updat like make
praluent relev growth contributor continu recommend purchas
commerci regulatori clinic ip risk associ market pipelin product
regeneron develop market therapi address varieti diseas
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
increas praluent end-us revenu estim assum lower
net price per patient higher volum consist weekend updat see
praluent revenu old vs new pjc consensu estim
page
good sold
product sale
collabor manufactur
collabor revenu
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
